Explore Business Standard
Explore Business Standard
The revenue stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Operating Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
PBDT stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Profit Before Tax stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Net Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This represents a per cent year-on-year *(YoY) decline for the same year.
| Category | Q2 FY25-26 | Q2 FY24-25 | Change % | FY24-25 | FY23-24 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 7,047.51 | 5,672.73 | 24.23 | 22,707.90 | 20,010.82 | 13.48 |
| Expenses | 4,706.18 | 4,332.37 | 8.63 | 17,424.59 | 16,200.30 | 7.56 |
| Other Income | 90.00 | 42.29 | 112.82 | 195.82 | 120.17 | 62.95 |
| Operating Profit | 197.59 | 113.16 | 74.61 | 5,479.13 | 3,930.69 | 39.39 |
| Depreciation | 316.77 | 256.92 | 23.30 | 1,169.26 | 1,196.81 | -2.30 |
| Interest | 107.59 | 70.87 | 51.81 | 294.87 | 311.61 | -5.37 |
| Profit Before Tax | 2,006.97 | 1,054.86 | 90.26 | 4,015.00 | 2,422.27 | 65.75 |
| Tax | 522.14 | 195.38 | 167.24 | 990.69 | 633.85 | 56.30 |
| Net Profit | 1,477.92 | 852.63 | 73.34 | 3,306.26 | 1,935.57 | 70.82 |
| Category | Q2 FY25-26 | Q2 FY24-25 | Change % | FY24-25 | FY23-24 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 4,068.28 | 4,106.20 | -0.92 | 16,967.50 | 14,666.50 | 15.69 |
| Expenses | 2,892.65 | 2,991.45 | -3.30 | 11,572.24 | 11,207.44 | 3.25 |
| Other Income | 662.68 | 32.62 | 1931.51 | 174.05 | 106.73 | 63.08 |
| Operating Profit | 3,716.40 | 3,071.10 | 21.01 | 5,569.31 | 3,565.79 | 56.19 |
| Depreciation | 174.72 | 145.77 | 19.86 | 647.69 | 724.75 | -10.63 |
| Interest | 27.78 | 17.55 | 58.29 | 84.50 | 56.35 | 49.96 |
| Profit Before Tax | 1,635.81 | 984.05 | 66.23 | 4,837.12 | 2,784.69 | 73.70 |
| Tax | 278.46 | 176.29 | 57.96 | 857.12 | 484.05 | 77.07 |
| Net Profit | 1,357.35 | 807.76 | 68.04 | 3,972.96 | 2,326.09 | 70.80 |
| Category | Q2 FY25-26 | Q1 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 7,047.51 | 6,268.34 | 12.43 |
| Expenses | 4,706.18 | 4,541.10 | 3.64 |
| Other Income | 90.00 | 79.04 | 13.87 |
| Operating Profit | 197.59 | 170.80 | 15.69 |
| Depreciation | 316.77 | 298.98 | 5.95 |
| Interest | 107.59 | 91.76 | 17.25 |
| Profit Before Tax | 2,006.97 | 1,415.54 | 41.78 |
| Tax | 522.14 | 194.08 | 169.03 |
| Net Profit | 1,477.92 | 1,219.03 | 21.24 |
| Category | Q2 FY25-26 | Q1 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 4,068.28 | 5,708.59 | -28.73 |
| Expenses | 2,892.65 | 2,978.95 | -2.90 |
| Other Income | 662.68 | 54.14 | 1124.01 |
| Operating Profit | 3,716.40 | 4,608.99 | -19.37 |
| Depreciation | 174.72 | 176.73 | -1.14 |
| Interest | 27.78 | 18.90 | 46.98 |
| Profit Before Tax | 1,635.81 | 2,588.15 | -36.80 |
| Tax | 278.46 | 460.08 | -39.48 |
| Net Profit | 1,357.35 | 2,128.07 | -36.22 |
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Data not available.
| Company | 1 Day | 1 Week | 1 Month | 3 Months | 6 Month | 1 Year |
|---|---|---|---|---|---|---|
| Data Not Found | ||||||
Drug firm Lupin on Wednesday said it will set up a new manufacturing facility in Coral Springs, Florida, entailing an investment of USD 250 million. With a projected cumulative investment of USD 250 million, including research & development, infrastructure and capital expenditures over a five-year period, the new site will have the capacity to accommodate the production of more than 25 critical respiratory medicines, the Mumbai-based drug maker said in a regulatory filing. The Florida-based plant would produce products like albuterol inhalers for children with asthma, it added. By strengthening domestic manufacturing and enhancing supply chain diversification, this critical project will enhance medicine security and strengthen the company's position as a global respiratory leader, it said. Locally, the infrastructure will generate over 200 new long-term, skilled jobs by 2030 in Broward County. "The expansion of Lupin's footprint in Coral Springs is a core part of our growth ...
